Tri-Heart Plus uses the same molecule as the leading competitor, making it just as effective at preventing heartworm disease and treating and controlling roundworms and hookworms.
Heartworm disease starts with a mosquito bite infecting your dog with worms that live and reproduce in the heart and pulmonary arteries. Keep your dog safe and stop the dreaded infection cycle with Tri-Heart Plus.
Provide your dog with a palatable beef-flavored chewable that provides premium protection for him and savings for you.
A taste test of Tri-Heart Plus Chewable Tablets vs. Heartgard Plus Chewables showed that dogs have no preference.
- Consistent heartworm medication keeps your dog protected
- Costs 20% less than Heartgard, making it affordable year-round
- Preventing heartworm costs 15x less than treating an infected dog
- Kill heartworm larvae in their tracks
- Treats and controls roundworms and hookworm parasites
- Enjoy year-round protection for your pet
- 94% of dogs love the chewable tablets
- In a taste test dogs proved to have no preference between Tri-Heart Plus and Heartgard Plus
INDICATIONS: For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for a month (30 days) after infection and for the treatment and control of ascarids (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense).
DOSAGE: Tri-Heart® Plus ivermectin/pyrantel chewable tablets should be administered orally at monthly intervals at the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb) and 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) of body weight. The recommended dosing schedule for prevention of canine heartworm disease and for the treatment and control of ascarids and hookworms is as follows:
Chewable Tablets per Month
Color Coding on Blister Card and Carton
Up to 25 lbs
26 to 50 lbs
51 to 100 lbs
Tri-Heart® Plus ivermectin/pyrantel chewable tablets are recommended for dogs 6 weeks of age and older. For dogs over 100 lbs, use the appropriate combination of these tablets.
ADMINISTRATION: Remove only one chewable tablet at a time from the blister card. Because most dogs find Tri-Heart® Plus chewable tablets palatable, the product can be offered to the dog by hand. Alternatively, it may be added intact to a small amount of dry food or placed in the back of the dog’s mouth for forced swallowing.
Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.
Tri-Heart® Plus chewable tablets should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog’s first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog’s last exposure to mosquitoes.
When replacing another heartworm preventive product in a heartworm disease preventive program, the first dose of Tri-Heart® Plus chewable tablets must be given within a month (30 days) of the last dose of the former medication.
If the interval between doses exceeds a month (30 days), the efficacy of ivermectin can be reduced. Therefore, for optimal performance, the chewable tablet must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with Tri-Heart® Plus chewable tablets and resumption of the recommended dosing regimen minimizes the opportunity for the development of adult heartworms.
Monthly treatment with Tri-Heart® Plus chewable tablets also provides effective treatment and control of ascarids (T. canis, T. leonina) and hookworms (A. caninum, U. stenocephala, A. braziliense). Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites.
EFFICACY: Tri-Heart® Plus chewable tablets given orally using the recommended dose and regimen, are effective against the tissue larval stage of D. immitis for a month (30 days) after infection and, as a result, prevent the development of the adult stage. Tri-Heart® Plus chewable tablets are also effective against canine ascarids (T. canis, T. leonina) and hookworms (A. caninum, U. stenocephala, A. braziliense).
ACCEPTABILITY: In acceptability trials, Tri-Heart® Plus chewable tablets were shown to be a palatable oral dosage form that was consumed at first offering by the majority of dogs.
PRECAUTIONS: All dogs should be tested for existing heartworm infection before starting treatment with Tri-Heart® Plus chewable tablets which are not effective against adult D. immitis. Infected dogs must be treated to remove adult heartworms and microfilariae before initiating a program with Tri-Heart® Plus chewable tablets.
While some microfilariae may be killed by the ivermectin in Tri-Heart® Plus chewable tablets at the recommended dose level, Tri-Heart® Plus chewable tablets are not effective for microfilariae clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.
Keep this and all drugs out of the reach of children. In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.
Store at controlled room temperature of 59-86° F (15-30° C). Protect product from light.
ADVERSE REACTIONS: In clinical field trials with ivermectin/pyrantel, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported following the use of ivermectin at the recommended dose: depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions and hypersalivation.